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Abstract
Objective. Chronic obstructive pulmonary disease (COPD) is a
progressive disease that causes significant mortality and morbidity
worldwide and is primarily caused by the inhalation of cigarette
smoke (CS). Lack of effective treatments for COPD means there is
an urgent need to identify new therapeutic strategies for the
underlying mechanisms of pathogenesis. Tristetraprolin (TTP)
encoded by the Zfp36 gene is an anti-inflammatory protein that
induces mRNA decay, especially of transcripts encoding
inflammatory cytokines, including those implicated in COPD.
Methods. Here, we identify a novel protective role for TTP in CS-
induced experimental COPD using Zfp36aa/aa mice, a genetically
modified mouse strain in which endogenous TTP cannot be
phosphorylated, rendering it constitutively active as an mRNA-
destabilising factor. TTP wild-type (Zfp36+/+) and Zfp36aa/aa active
C57BL/6J mice were exposed to CS for four days or eight weeks,
and the impact on acute inflammatory responses or chronic
features of COPD, respectively, was assessed. Results. After four
days of CS exposure, Zfp36aa/aa mice had reduced numbers of
airway neutrophils and lymphocytes and mRNA expression levels
of cytokines compared to wild-type controls. After eight weeks,
Zfp36aa/aa mice had reduced pulmonary inflammation, airway
remodelling and emphysema-like alveolar enlargement, and lung
function was improved. We then used pharmacological treatments
in vivo (protein phosphatase 2A activator, AAL(S), and the
proteasome inhibitor, bortezomib) to promote the activation and
stabilisation of TTP and show that hallmark features of CS-induced
experimental COPD were ameliorated. Conclusion. Collectively, our
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study provides the first evidence for the therapeutic potential of
inducing TTP as a treatment for COPD.
Keywords: chronic obstructive pulmonary disease, inflammation,
protein phosphatase 2A, tristetraprolin, ubiquitin–proteasome
system
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a
progressive lung disease that is characterised by
chronic airway inflammation, airway remodelling,
emphysema and impaired lung function.1 It is now
the third leading cause of morbidity and death
worldwide and imposes a substantial
socioeconomic burden.2 The inhalation of cigarette
smoke (CS) is a major risk factor for COPD.3 Other
factors such as wood and cooking smoke,
occupational exposure to dust and chemicals and
air pollution have also been associated with the
aetiology of COPD.4 Current mainstay treatments
for COPD are bronchodilators and inhaled steroids,
which are only partially effective in managing
disease symptoms and do not treat the underlying
causes or halt the progression of the disease.5
Hence, there is an urgent need to understand the
mechanisms of disease pathogenesis and identify
new potential therapeutic targets.
Tristetraprolin (TTP) encoded by the Zfp36 gene
is an anti-inflammatory protein that post-
transcriptionally suppresses many pro-
inflammatory factors, including cytokines that are
known to drive the pathogenesis of COPD. TTP
induces mRNA decay by binding to the adenylate
and uridylate (AU)-rich elements in the 3’-
untranslated regions of target cytokines.6–8 The
mRNA-destabilising function of TTP is regulated
by the phosphorylation and dephosphorylation of
two particular residues, serines 52 and 178 of
murine TTP (serines 60 and 186 of the human
orthologue).9 It is phosphorylated and inactivated
by mitogen-activated protein kinase (MAPK)-
activated protein kinase 2 (MK2), leading to the
stabilisation of target mRNA.10 Protein
phosphatase 2A (PP2A) can dephosphorylate TTP,
enhancing its activity and promoting the de-
stabilisation of target mRNA.11,12 However, active
TTP is targeted by the ubiquitin–proteasome
system for degradation.13 In these ways, TTP is
controlled by phosphorylation at key serines that
act as a molecular switch, phosphorylated – OFF
and hypophosphorylated – ON. Thus, TTP is a
tractable target for novel anti-inflammatory
treatments for COPD.
The role of TTP in lung inflammation and
respiratory disease has not been studied. Given
that TTP regulates the mRNA stability of multiple
inflammatory genes, including those involved in
COPD, such as IL-6, TNF-a and the chemokines
CXCL1 and CXCL2 that are functional homologs of
human IL-8, we hypothesised that active TTP would
be beneficial in COPD.14–16 To test this, we utilised
a genetically modified constitutively TTP active
mouse strain in which serine 52 and serine 178 of
the endogenous TTP protein are replaced with non-
phosphorylatable alanine residues (Zfp36aa/aa).17
The substitution of two amino acids of the
endogenous TTP protein renders it constitutively
active as an mRNA-destabilising factor. We
examined the impact of active TTP in experimental
CS-induced COPD using Zfp36aa/aa mice. We show for
the first time that active TTP protects mice from
hallmark features of experimental COPD by reducing
pulmonary inflammation, airway remodelling,
alveolar enlargement and improving lung function.
Hence, we identify a previously unrecognised role
for active TTP in regulating CS-induced
inflammatory responses and the pathogenesis of
experimental COPD. Thus, pharmacological
strategies that promote TTP activity may be novel
therapies for COPD. We then tested this by treating
wild-type C57BL/6J mice with a PP2A activator
(AAL(S)) that activates TTP, alone and in combination
with the proteasome inhibitor, bortezomib (BORT),
to stabilise TTP, and assessed the impact on the
induction of experimental CS-induced COPD.
Treatment ameliorated the hallmark features of
disease paving the way for future drug
development.
RESULTS
Acute CS-induced pulmonary inflammation
is reduced in TTP active mice
To evaluate the impact of active TTP on acute
CS-induced inflammatory responses in the lung,
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wild-type and TTP active (Zfp36aa/aa) mice were
exposed to CS for four days (Figure 1a) and
pulmonary inflammation was assessed in BAL
fluid. CS exposure of wild-type mice significantly
increased the numbers of total leucocytes,
neutrophils, macrophages and lymphocytes in BAL
fluid compared to normal air-exposed wild-type
controls (Figure 1b). CS exposure of Zfp36aa/aa
mice significantly increased total neutrophils and
leucocytes, but not macrophages or lymphocytes
Figure 1. Acute cigarette smoke (CS)-induced pulmonary inflammation is reduced in tristetraprolin (TTP) active mice. (a) Wild-type (Zfp36+/+) and
TTP active (Zfp36aa/aa) C57BL/6J mice were exposed to CS or normal air for four days. (b) Total leucocytes, neutrophils, macrophages and
lymphocytes in bronchoalveolar lavage (BAL) fluid. (c) Interleukin-6 (Il6), tumor necrosis factor-alpha (Tnfa), chemokine C-X-C motif ligand (Cxcl)1
and Cxcl2 mRNA expression levels in lung homogenates. Data (n = 5 or 6) are presented as means  sem from two independent experiments.
*represents P ≤ 0.05 compared to Zfp36+/+ Air, # represents P ≤ 0.05 compared to Zfp36aa/aa Air, and + represents P ≤ 0.05 compared to
Zfp36+/+ Smoke (Smk).
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compared to their air-exposed Zfp36aa/aa controls.
Notably, CS-exposed Zfp36aa/aa mice had reduced
numbers of neutrophils and lymphocytes
compared to CS-exposed wild-type mice.
Given that CS-exposed Zfp36aa/aa mice had
reduced pulmonary cellular inflammation, mRNA
expression of associated pro-inflammatory
cytokines and chemokines that are also TTP
targets and involved in COPD pathogenesis was
assessed in lung homogenates. Acute CS exposure
of both wild-type and Zfp36aa/aa mice for 4 days
increased the mRNA expression of the TTP targets
Il6, Tnfa, Cxcl1 and Cxcl2 compared to air-exposed
wild-type and Zfp36aa/aa controls (Figure 1c).
There was a significant reduction in the mRNA
expression of the pro-inflammatory cytokines, Il6
and Tnfa, in CS-exposed Zfp36aa/aa mice compared
to CS-exposed wild-type controls (Figure 1c).
There was no change in pro-inflammatory
chemokine Cxcl1 mRNA expression, but there was
a significant reduction in Cxcl2 mRNA expression
in CS-exposed Zfp36aa/aa mice compared to CS-
exposed wild-type controls.
Chronic CS-induced pulmonary
inflammation is reduced in TTP active mice
Since pulmonary inflammation is a key driver of
chronic pathologies, we next assessed the impact
of active TTP on chronic features of experimental
CS-induced COPD. Wild-type and Zfp36aa/aa mice
were exposed to CS for 8 weeks (Figure 2a), and
chronic inflammatory responses were assessed. CS
exposure of both strains significantly increased
numbers of total leucocytes, neutrophils,
macrophages and lymphocytes in BAL fluid
compared to their respective air-exposed controls
(Figure 2b). Notably, CS-exposed Zfp36aa/aa mice
had reduced total leucocytes and neutrophils in
BAL fluid, but not macrophages or lymphocytes
compared to CS-exposed wild-type controls.
Next, inflammatory cell numbers in the
parenchyma were assessed. Eight weeks of CS
exposure of both wild-type and Zfp36aa/aa mice
significantly increased the numbers of
inflammatory cells in the parenchyma of both
strains compared to their respective air-exposed
controls (Figure 2C). However, the numbers of
parenchymal inflammatory cells in CS-exposed
Zfp36aa/aa were significantly reduced compared to
CS-exposed wild-type controls.
Next, the mRNA expression of pro-inflammatory
cytokines and chemokines in the lungs after
8 weeks of CS exposure was assessed. CS exposure
of both wild-type and Zfp36aa/aa mice increased
the mRNA expression of Il6, Tnfa, Cxcl1 and Cxcl2
compared to their respective air-exposed controls
(Figure 2d). There were no significant differences
in the levels of mRNA expression of Il6, Tnfa or
Cxcl1 between CS-exposed wild-type and Zfp36aa/aa
mice, but there was a significant reduction in the
expression of Cxcl2 in CS-exposed Zfp36aa/aa mice
compared to CS-exposed wild-type controls.
Chronic CS-induced small airway
remodelling is reduced in TTP active mice
We previously showed that mice develop small
airway remodelling characterised by increases in
collagen deposition, epithelial cell area and
numbers of nuclei around and in the small
airways in experimental COPD.18–23 As expected,
chronic CS exposure of wild-type mice increased
collagen deposition around the airways compared
to normal air-exposed wild-type controls
(Figure 3a). CS-exposed Zfp36aa/aa mice were
protected against collagen deposition with no
differences compared to normal air-exposed
Zfp36aa/aa controls and had significantly reduced
deposition compared to CS-exposed wild-type
controls. In line with these data, CS exposure of
wild-type mice increased the mRNA expression of
the pro-fibrotic/remodelling protein Fn in the
lungs compared to air-exposed controls, but there
was no increase in Zfp36aa/aa exposed to CS
compared to their controls. Accordingly, CS-
exposed Zfp36aa/aa had significantly lower
expression of Fn in the lungs compared to CS-
exposed wild-type mice. CS exposure also
significantly increased small airway epithelial cell
area in wild-type mice compared to air-exposed
wild-type controls, but this did not occur in
Zfp36aa/aa compared to their air-exposed controls.
Again, CS-exposed Zfp36aa/aa mice had
significantly reduced small airway epithelial cell
area compared to CS-exposed wild-type controls.
We then determined whether the increase in
epithelial cell area was associated with an increase
in the number of nuclei in the small airways,
which is indicative of increased epithelial cell
number. CS exposure increased nuclei numbers in
the small airways of both wild-type and Zfp36aa/aa
mice. However, for this parameter there was no
difference in nuclei numbers in the small airways
between CS-exposed wild-type and Zfp36aa/aa
mice.
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Figure 2. Chronic cigarette smoke (CS)-induced pulmonary inflammation is reduced in tristetraprolin (TTP) active mice. (a) Wild-type (Zfp36+/+)
and TTP active (Zfp36aa/aa) C57BL/6J mice were exposed to CS or normal air for eight weeks. (b) Total leucocytes, neutrophils, macrophages and
lymphocytes in bronchoalveolar lavage (BAL) fluid. (c) Numbers of parenchymal inflammatory cells (arrowheads) were determined in haematoxylin
and eosin-stained lung sections. Scale bars = 20 lm. (d) Interleukin-6 (Il6), tumor necrosis factor-alpha (Tnfa), chemokine C-X-C motif ligand
(Cxcl)1 and Cxcl2 mRNA expression were determined in lung homogenates. Data (n = 6-8) are presented as means  sem from two independent
experiments. *represents P ≤ 0.05 compared to Zfp36+/+ Air, # represents P ≤ 0.05 compared to Zfp36aa/aa Air, and + represents P ≤ 0.05
compared to Zfp36+/+ Smoke (Smk).
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Figure 3. Chronic cigarette smoke (CS)-induced airway remodelling, emphysema and impaired lung function are reduced in tristetraprolin (TTP)
active mice. Wild-type (Zfp36+/+) and TTP active (Zfp36aa/aa) C57BL/6J mice were exposed to CS or normal air for eight weeks. (a) Area of
collagen deposition (lm2) per basement membrane (BM) perimeter (lm) in Masson’s trichrome-stained lung sections. Scale bars = 50 lm.
Fibronectin mRNA expression was determined in lung homogenates. Small airway epithelial thickness in terms of epithelial cell area (lm2) per BM
perimeter (lm) in haematoxylin and eosin (H&E)-stained lung sections. Scale bars = 50 lm. Number of epithelial cells in H&E-stained lung
sections were assessed by enumerating the number of nuclei per 100 lm of BM perimeter. (b) Alveolar diameter (lm) was determined in
haematoxylin and eosin-stained lung sections using the mean linear intercept and destructive index techniques. Scale bars = 50 lm. (c) Matrix
metalloproteinase (Mmp)12 mRNA expression was determined in lung homogenates. (d) Lung function was assessed in terms of airway
resistance, total lung capacity, forced expiratory volume in 100 s/forced vital capacity (FEV100/FVC) ratio, pressure–volume loops and lung
compliance at 30 cmH20. Data (n = 6–8) are presented as means  sem from two independent experiments. *represents P ≤ 0.05 compared to
Zfp36+/+ Air, # represents P ≤ 0.05 compared to Zfp36aa/aa Air, + represents P ≤ 0.05 compared to Zfp36+/+ Smoke (Smk), and ns represents not
significant.
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Chronic CS-induced emphysema-like
alveolar enlargement and impaired lung
function are reduced in TTP active mice
We previously showed that mice develop
emphysema-like alveolar enlargement and
impaired lung function after eight weeks of CS
exposure.18–24 In this study, chronic CS exposure
of wild-type mice for 8 weeks resulted in
increased alveolar diameter and septal damage,
which were assessed using the mean linear
intercept and destructive index methods,
respectively, compared to air-exposed wild-type
controls (Figure 3b). In CS-exposed Zfp36aa/aa
groups, there were increases in alveolar diameter
but not septal damage, compared to their air-
exposed controls. Notably, alveolar diameter and
septal damage were also significantly reduced in
CS-exposed Zfp36aa/aa mice compared to CS-
exposed wild-type controls.
We then assessed the impact of active TTP on
matrix metalloproteinase-12 (MMP-12) as major
protease associated with inducing emphysema. CS
exposure of both wild-type and Zfp36aa/aa mice
increased the mRNA expression Mmp12 in whole
lung tissue compared to their respective controls
(Figure 3c). Notably, and concomitant with the
reduction in emphysema, the expression of MMP-
12 was significantly reduced in CS-exposed
Zfp36aa/aa mice compared to CS-exposed wild-type
controls.
Next, we assessed the potential effects of active
TTP and suppressed inflammation, remodelling
and emphysema on functional impacts and
improved lung function in experimental COPD. CS
exposure of wild-type mice increased airway
resistance and total lung capacity and reduced
FEV100/FVC ratio (Figure 3d) compared to air-
exposed controls. Importantly, Zfp36aa/aa mice
were protected against changes in airway
resistance, total lung capacity and FEV100/FVC
ratio, which were the same as in air-exposed
Zfp36aa/aa controls. Airway resistance and total
lung capacity were significantly reduced, while
FEV100/FVC ratio was significantly increased in CS-
exposed Zfp36aa/aa mice compared to CS-exposed
wild-type controls. CS exposure of wild-type mice
also increased compliance, determined during a
pressure–volume loop manoeuvre compared to
air-exposed controls. CS-exposed Zfp36aa/aa mice
were protected against changes in pressure–
volume loops and lung compliance, which were
the same as in their air-exposed controls.
BORT and BORT + AAL(S) treatment reduced
acute CS-induced pulmonary inflammation
Collectively, our data revealed that active TTP
suppresses the hallmark features of human
disease in CS-induced experimental COPD. These
data suggest that pharmacological strategies that
promote the activation and stabilisation of TTP
are novel anti-inflammatory treatments with the
potential to prevent irreversible damage and/or
the progression of COPD. We tested this potential
by examining the effects of treating mice with a
PP2A activator (AAL(S)) to activate TTP, alone and
in combination with the proteasome inhibitor,
bortezomib (BORT), to stabilise TTP, on the
induction of experimental CS-induced COPD.
We first evaluated the impact of treatments on
acute CS-induced inflammation in the lungs
(Figure 4a). Mice were treated daily with vehicle,
BORT, AAL(S) or BORT + AAL(S), immediately
before CS exposure for four days and controls
were vehicle-treated. Pulmonary cellular
inflammation was increased in BAL fluid of
vehicle-treated CS-exposed compared to air-
exposed mice (Figure 4b). Notably, BORT and
BORT + AAL(S) treatment significantly reduced the
numbers of neutrophils and lymphocytes in BAL
fluid compared to vehicle-treated CS-exposed
mice. Lymphocytes were significantly reduced
with either treatment alone or in combination.
We then assessed the impact of treatments on
the expression of TTP targets Il6, Tnfa, Cxcl1 and
Cxcl2. The mRNA expression of Il6, Tnfa
(Figure 4c), Cxcl1 and Cxcl2 (not shown) was
significantly increased in vehicle-treated CS-
exposed compared to air-exposed mice. Notably,
there was a significant reduction in the mRNA
expression of the pro-inflammatory cytokine and
archetypal TTP target TNF-a in CS-exposed mice
treated with BORT or BORT + AAL(S) compared to
vehicle-treated CS-exposed mice (Figure 4c). There
was also a non-significant trend to a reduction in
IL-6, but the chemokines were unaffected by
treatment (not shown).
BORT and BORT + AAL(S) treatment reduced
chronic CS-induced pulmonary inflammation
in experimental COPD
We next assessed the impact of treatments on
chronic features of CS-induced experimental COPD
(Figure 5a). Vehicle-treated chronically CS-exposed
mice had significantly increased total leucocytes,
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neutrophils, macrophages and lymphocytes in BAL
fluid, compared to vehicle-treated air-exposed
controls. Notably, BORT and BORT + AAL(S)
treatment of CS-exposed mice significantly
reduced the numbers of neutrophils and
lymphocytes in BAL fluid compared to vehicle-
treated CS-exposed mice. Given that these
inflammatory cells were also repressed with
Figure 4. Acute cigarette smoke (CS)-induced pulmonary inflammation is reduced in BORT- and BORT + AAL(S)-treated mice. (a) Wild-type
C57BL/6J mice were treated daily (i.p.) with vehicle, BORT (0.2 mg kg1), AAL(S) (0.8 mg kg
1) or BORT + AAL(S) and exposed to CS for four
days. Controls were vehicle-treated and exposed to normal air. (b) Total leucocytes, neutrophils, macrophages and lymphocytes in
bronchoalveolar lavage (BAL) fluid. (c) Interleukin-6 (Il6) and tumor necrosis factor-alpha (TNF-a) mRNA expression were determined in lung
homogenates. Data (n = 6–8) are presented as means  sem from two independent experiments. *represents P ≤ 0.05 compared to
Air + vehicle and + represents P ≤ 0.05 compared to Smoke + vehicle.
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treatment in acute CS exposure model (Figure 4b),
these data suggest that the effect of treatments
on neutrophil and lymphocyte inflammation was
sustained throughout chronic CS exposure.
Although we measured pro-inflammatory mRNA
expression after chronic CS exposure (Figure 5c),
there was no effect of treatments. This suggests
that it is the early-stage impact of TTP that is
Figure 5. Chronic cigarette smoke (CS)-induced pulmonary inflammation is reduced in BORT- and BORT + AAL(S)-treated mice. (a) Wild-type
C57BL/6J mice were treated daily (i.p.) with vehicle, BORT (0.2 mg kg1), AAL(S) (0.8 mg kg
1) or BORT + AAL(S) and exposed to CS for eight
weeks. Controls were vehicle-treated and exposed to normal air. (b) Total leucocytes, neutrophils, macrophages and lymphocytes in
bronchoalveolar lavage (BAL) fluid. (c) Interleukin-6 (Il6), tumor necrosis factor-alpha (TNF-a), chemokine C-X-C motif ligand (Cxcl)1 and Cxcl2
mRNA expression were determined in lung homogenates. Data (n = 6–8) are presented as means  sem from two independent experiments.
*represents P ≤ 0.05 compared to Air + vehicle and + represents P ≤ 0.05 compared to Smoke + vehicle.
ª 2019 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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likely most important or that other factors are
involved.
BORT and BORT + AAL(S) treatment reduced
chronic CS-induced small airway
remodelling but not emphysema-like
alveolar enlargement or lung function
impairment in experimental COPD
We next examined the effect of the treatments
on the chronic features of experimental COPD.
Vehicle-treated chronically CS-exposed mice had
increased collagen deposition (Figure 6a) and
epithelial cell area around the small airways
compared to vehicle-treated air-exposed controls.
Importantly, both of these hallmark features of
small airway remodelling were suppressed by
treatment with BORT + AAL(S). Moreover, BORT
alone was sufficient to significantly reduce CS-
induced collagen deposition around the small
airways, and there was a trend towards lower
epithelial cell area although the reduction was
not significant (P = 0.0722).
Vehicle-treated chronically CS-exposed mice also
had emphysema-like alveolar enlargement,
compared to vehicle-treated air-exposed controls
(Figure 6b). While there was a trend towards
repression in destructive index in CS-exposed mice
treated with BORT and BORT + AAL(S), the
reduction was not significant (P = 0.0783). There
were no other changes in alveolar diameter or
destructive index.
Finally, we assessed the potential of treatments
to suppress CS-induced impairment of lung
function in experimental COPD. Vehicle-treated
chronically CS-exposed mice had increased total
lung capacity, inspiratory capacity and P-V loop
extracted lung compliance (Figure 6c), compared
to vehicle-treated air-exposed controls. However,
no treatments (alone or in combination) had
significant effects on CS-induced lung function
impairment.
DISCUSSION
In this study, a previously unrecognised role for
TTP in suppressing CS-induced pulmonary
inflammation, airway remodelling, emphysema
and impaired lung function was identified. Using
established mouse models of CS-induced
experimental COPD and TTP constitutively active
Zfp36aa/aa mice, we demonstrate that the presence
of active TTP significantly reduced CS-induced
pulmonary cellular inflammation, characterised by
reduced neutrophils in BAL fluid and numbers of
inflammatory cells in the parenchyma. The
reduced cellular inflammation was associated with
concomitant reductions in the expression of pro-
inflammatory cytokines and chemokines that
recruit neutrophils to the airway lumen and
induce pulmonary inflammation in response to CS
exposure. Mice expressing active TTP were also
protected against chronic disease features
including CS-induced small airway remodelling,
with no excess collagen deposition nor increases
in small airway epithelial cell area. Importantly,
these mice also had reduced emphysema-like
alveolar enlargement and improved lung
function. Treatment of CS-exposed wild-type mice
with the novel PP2A and TTP activator, AAL(S),
and the clinically used proteasome inhibitor,
BORT, also suppressed the important hallmark
features of human disease of neutrophilic
inflammation and airway remodelling in
experimental COPD. Collectively, these data show
for the first time that inducing TTP may have
therapeutic potential in COPD and other chronic
respiratory diseases, underscoring the need for
drug discovery and development programmes that
promote TTP.
CS exposure for four days enabled the
evaluation of early smoke-induced inflammatory
responses in the lung,25,26 while exposure for
eight weeks induces the development of the
hallmark features of COPD that are observed in
humans.18,21,22,27 These include pulmonary
inflammation (chronic bronchitis), small airway
remodelling, emphysema-like alveolar
enlargement and impaired lung function.28 The
TTP active mouse (Zfp36aa/aa) is a valuable and
novel tool to investigate roles in regulating
inflammatory responses in the lung and in the
pathogenesis of experimental COPD. Mice
deficient in TTP develop severe inflammation and
have a high mortality rate in the absence of
exogenous inflammatory stimuli, and therefore,
using these mice to study inflammatory diseases is
not appropriate.15 Thus, we utilised TTP active
mice to show that active TTP represses
inflammation and protects mice against CS-
induced experimental COPD. Notably, as in
humans, the hallmark features of COPD do not
respond well to corticosteroid treatment, so the
induction of TTP is an alternative approach.18
CS exposure for both four days and eight weeks
resulted in increased pulmonary inflammation
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Figure 6. Chronic cigarette smoke (CS)-induced airway remodelling but not emphysema or impaired lung function is reduced in BORT- and
BORT + AAL(S)-treated mice. Wild-type C57BL/6J mice were treated daily (i.p.) with vehicle, BORT (0.2 mg kg
1), AAL(S) (0.8 mg kg
1) or
BORT + AAL(S) and exposed to CS for eight weeks. Controls were vehicle-treated mice exposed to normal air. (a) Area of collagen deposition
(lm2) per basement membrane (BM) perimeter (lm) in Masson’s trichrome-stained lung sections. Scale bars = 50 lm. Small airway epithelial
thickness in terms of epithelial cell area (lm2) per BM perimeter (lm) in haematoxylin and eosin (H&E)-stained lung sections. Scale bars = 50 lm.
(b) Alveolar diameter (lm) was determined in haematoxylin and eosin-stained lung sections using the mean linear intercept and destructive index
technique. Scale bars = 50 lm. Lung function was assessed in terms of (c) total lung capacity, inspiratory capacity, pressure–volume loops and
lung compliance at 30 cm H20. Data (n = 6–8) are presented as means  sem from two independent experiments. *represents P ≤ 0.05
compared to Air + vehicle and + represents P ≤ 0.05 compared to Smoke + vehicle.
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characterised by exaggerated levels of total
leucocytes, neutrophils, macrophages and
lymphocytes in the airway lumen. These cells have
previously been shown to be increased in both
experimental and human COPD.18,21,29–31 CS-
exposed Zfp36aa/aa mice had significantly reduced
influx of neutrophils in the airway lumen after
four days and eight weeks of CS exposure
compared to CS-exposed wild-type controls.
Neutrophils have been implicated in the
development of alveolar destruction in COPD
through the release of serine proteases.32,33
Increased levels of sputum neutrophils have also
been associated with rapid declines in lung
function and increased COPD disease
severity.29,31,34 We also quantified neutrophil
numbers in the lung tissue by flow cytometry, but
did not observe any difference between CS-
exposed Zfp36++/++ and Zfp36aa/aa mice (data not
shown). In contrast, CS-exposed Zfp36aa/aa mice
did have reduced numbers of parenchymal-
associated inflammatory cells in lung tissue after
eight weeks of CS exposure. These cells were
predominantly macrophages, which were not
reduced in the BAL fluid of CS-exposed Zfp36aa/aa
mice. Notably, the inflammatory cell profile from
BAL fluid represents that from distal airways and
alveoli while the inflammatory cells in lung tissue
represent that from the parenchyma. These
findings suggest that active TTP regulates
inflammatory responses to CS in various parts of
the airways and lungs. This likely results from
active TTP inducing the degradation of mRNA of
target cytokines such as Tnfa and Cxcl2 that
recruit inflammatory cells.14,15 Our findings are
consistent with those of others that have
previously shown that a lack of TTP leads to
severe inflammation as a result of exaggerated
TNF-a expression.15 Notably, a recent study
demonstrated that exposure to CS significantly
reduced TTP levels in mouse alveolar macrophages
and rat alveolar epithelial cells.35 This led to
increased Tnfa mRNA stability and higher
subsequent levels of TNF-a in these cells.
In support of our inflammatory cell data, CS
exposure also increased the mRNA expression of
key pro-inflammatory cytokines Il6 and Tnfa and
chemokines Cxcl1 and Cxcl2, in both CS-exposed
wild-type and Zfp36aa/aa mice. Levels of IL-6 are
increased in the sputum of COPD patients and are
associated with reduced lung function.36,37
Increased expression of TNF-a occurs in mice and
humans following CS exposure.18,38,39 This cytokine
induces the expression of the neutrophil
chemoattractants CXCL1 and CXCL2.40 Notably, the
mRNA expression of Il6 and Tnfa was significantly
lower in the lungs of Zfp36aa/aa mice compared to
wild-type controls after four days, but not after
eight weeks of CS exposure. This may be attributed
to differences in acute versus chronic phases of the
disease, where the induction of pro-inflammatory
cytokines predominates in the acute phase, while
this is less critical in the chronic phase. There was a
significant reduction in the mRNA expression of
Cxcl2, but not Cxcl1 in the lungs of CS-exposed
Zfp36aa/aa mice compared to CS-exposed wild-type
controls after eight weeks of CS exposure. Both
these chemokines are functional homologs of
human IL-8 and are increased in both mouse
models and human COPD.18,41,42 The decreased
Cxcl2 expression is consistent with the reduced
neutrophil numbers in the BAL of CS-exposed
Zfp36aa/aa mice. Since CXCL2 is a known target of
TTP,14 our findings suggest that the presence of
active TTP may induce the decay of Cxcl2 mRNA in
response to CS, and prevent the recruitment of
neutrophils to the lung.
The continuous inflammatory response in COPD
leads to the development of airway remodelling.43
Excessive production of extracellular matrix
proteins such as fibronectin by airway epithelial
and smooth muscle cells in response to CS is
linked to the development of airway remodelling
in COPD.44,45 In our study, while CS exposure
increased collagen deposition around the airways
and increased airway epithelial cell thickness in
wild-type mice, these effects were not observed in
CS-exposed Zfp36aa/aa mice, highlighting a role for
active TTP in suppressing airway remodelling.
Increased collagen deposition occurs in
emphysematous lung tissue and has been
postulated to be associated with tissue destruction
in human emphysema.46–48 Increased airway
epithelial thickness has also been observed in
COPD patients.49 The levels of the extracellular
matrix protein fibronectin are also elevated in the
airways of COPD patients, contribute to airway
remodelling and have an inverse correlation with
lung function in COPD patients.44,45 The reduction in
airway remodelling observed in Zfp36aa/aa mice was
associated with reduced levels of fibronectin in the
lung.
We previously showed that chronic CS exposure
leads to emphysema-like alveolar enlargement in
experimental COPD.18,19,21,23,24,50,51 In our current
study, Zfp36aa/aa mice were protected against CS-
2019 | Vol. 8 | e1084
Page 12
ª 2019 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology Inc.
TTP suppresses COPD pathogenesis PM Nair et al.
induced alveolar enlargement. This was associated
with reduced mRNA expression of Mmp12 in the
lungs. MMP-12 is a proteinase that is primarily
produced by macrophages and plays a role in the
destruction of alveolar walls and the development
of emphysema.52–54 Mice deficient in MMP-12 are
protected against CS-induced emphysema.32
Similarly, guinea pigs exposed to CS for 6 months
and treated with the dual MMP-9/MMP-12
inhibitor were also protected against CS-induced
emphysema 55. Microarray data from our previous
study showed reduced expression of MMP12
by ~ 50% in LPS-treated Zfp36aa/aa compared to
LPS-treated Zfp36++/++ bone marrow-derived
macrophages, suggesting that MMP12 is highly
likely a TTP target.56 Pulmonary MMPs degrade
collagen and elastin that promote neutrophil and
macrophage influx, and are also associated with
gas trapping and small airways remodelling in
COPD.57,58 In our study, enhancing TTP activity
reduced MMP12-expressing macrophages that
occur alongside reductions in remodelling and
alveolar enlargement. Thus, we find that the
reduction in MMP12 may contribute to
amelioration of disease in Zfp36aa/a mice.
Impairment of lung function and breathing
difficulties are the most important features in
COPD patients. CS exposure of wild-type mice for
eight weeks resulted in impaired lung function
with increased airway resistance and total lung
capacity, reduced FEV100/FVC ratio and increased
compliance. Importantly, CS-exposed Zfp36aa/aa
mice did not have impaired lung function.
Protection against increased airway resistance in
CS-exposed Zfp36aa/aa is consistent with the
decrease in collagen deposition around the
airways, while no increases in total lung capacity
or decreases in FEV100/FVC ratio are consistent
with reduced alveolar enlargement. Taken
together, our findings suggest that active TTP
protects against a broad range of deleterious
effects of CS exposure on lung function. This may
be due to the ability of active TTP to induce the
mRNA decay of pro-inflammatory cytokines and
chemokines, which then reduces pulmonary
inflammation in response to CS and subsequently
leads to reduced features of airway remodelling
and emphysema and consequently improve lung
function.
Our study highlights the importance of having
active TTP to control CS-induced inflammation,
pulmonary remodelling, emphysema and impaired
lung function in mice. Given that our CS-induced
experimental COPD mouse model is corticosteroid
resistant, we have discovered that active TTP
represses inflammation and the hallmark features
of human COPD in vivo when corticosteroids
cannot. As inflammation leads to progressive and
irreversible tissue damage in COPD, our data also
suggest that pharmacotherapeutic strategies
targeting TTP represent novel anti-inflammatory
treatments that may not merely ameliorate the
symptoms but may be viable interventions for
preventing irreversible damage and/or the
progression of COPD. We assessed this by
systemically treating wild-type mice with the novel
PP2A and TTP activator, AAL(S), alone and in
combination with the proteasome inhibitor, BORT.
Notably, the combination of treatments exerted a
sustained repression of pulmonary inflammation
induced after 4 days and 8 weeks of CS exposure.
The repression of neutrophils is particularly
noteworthy, as neutrophilic inflammation in
respiratory disease is refractory to corticosteroid
treatment.18,59–62 While the impact of treatments
on pro-inflammatory cytokine and chemokine
mRNA expression levels in the lungs after acute CS
exposure was not as striking as the repression in TTP
active mouse, BORT + AAL(S) significantly repressed
Tnfa mRNA levels after four days, and features of
CS-induced airway remodelling at eight weeks were
ameliorated. This is consistent with inflammation
being a major driver of COPD pathogenesis and
that developing therapies that restrain
inflammation in conditions that are refractory to
corticosteroids will be a clinical advance.
Treatments did not alter CS-induced emphysema-
like alveolar enlargement, nor lung function
impairment. However, an important point is that
the efficacy of treatments has not been optimised.
They were administered intraperitoneally in
standard dosing regimens, but these have not been
refined to achieve maximum benefit in COPD. It is
unknown whether the treatments reach the
required tissues, whether exposure was for a
sufficient period or whether administration directly
to the lung would be more effective. The beneficial
effects of these treatments would be maximised by
performing drug development and formulation
studies that optimise their efficacy that may see
improve efficacy on suppressing chronic disease
features. Further drug discovery is underway to
develop these and other efficacious agents for
pulmonary delivery. It is also important to note that
we did not determine whether treatment activated
and stabilised TTP expression. The amount of TTP
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protein and the mRNA-destabilising activity of
TTP are not directly related, and it is the
phosphorylation status of TTP that determines its
functional activity.9 Determining the amount of TTP
in tissue will not indicate TTP activity. It is currently
technically difficult to measure TTP activity
(unphosphorylated form) and is beyond the scope
of this study.
These data build upon our recent studies. We
previously showed that PP2A activators (including
AAL(S)) enhanced TTP anti-inflammatory function
and repressed cytokine production in airway
epithelial cells in vitro.63,64 In vivo, we also showed
that targeting PP2A and proteasome activity
ameliorates features of allergic airway disease; an
effect speculated to be due to increased TTP
activity.65 Our study also aligns with studies by the
Clark group 66, where TTP active mice had an hypo-
inflamed phenotype and were protected against
developing inflammatory arthritis. There, AAL(S)
reduced inflammation and prevented bone erosion
in vivo. We showed the effects of PP2A activators
in vitro were mediated via TTP activation.66
Notably, others have shown that PP2A activity is
significantly reduced in bronchial epithelial cells
from COPD patients.67 While a direct link between
TTP and PP2A activity was not investigated in that
study, we propose that loss of PP2A activity may
lead to loss of TTP function and that enhancing
PP2A activity could be beneficial in COPD.
Collectively, these data suggest that TTP is a
negative regulator of inflammation and confers
protection from the development of CS-induced
emphysema, airway remodelling and lung function
impairment (Figure 7). These studies support the
compelling hypothesis that treating inflammation by
targeting TTP with novel drug modalities (e.g. PP2A
activators) is future pharmacotherapeutic strategies
for treating corticosteroid-insensitive respiratory
diseases (including COPD) and, more broadly, may
offer exciting potential for novel treatments for
inflammatory diseases such as arthritis.
Figure 7. Proposed mechanisms of how active tristetraprolin (TTP) confers protection against the development of cigarette smoke (CS)-induced
experimental COPD. CS exposure increases the messenger ribonucleic acid (mRNA) expression of inflammatory mediators resulting in pulmonary
inflammation. Ongoing inflammation drives the development of airway remodelling and emphysema. These features collectively result in lung
function decline. Active TTP degrades the mRNA of inflammatory mediators, preventing the development of pulmonary inflammation, airway
remodelling, emphysema and consequent lung function decline. TTP, tristetraprolin; mRNA, messenger ribonucleic acid; COPD, chronic
obstructive pulmonary disease.
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METHODS
Ethics statement
This study was performed in strict accordance with the
recommendations in the Australian code of practice for the
care and use of animals for scientific purposes issued by the
National Health and Medical Research Council of Australia.
All protocols were approved by the Animal Ethics
Committee of The University of Newcastle.
Experimental COPD
Female, 6–8 weeks old, wild-type littermates (Zfp36++/++) or
Zfp36aa/aa mice (generated on a C57BL/6J background)17 were
exposed to normal air or CS through the nose only for four
days (acute) or eight weeks (chronic) using well-established
methods.18–24,30,50,51,68–70 Exposures are equivalent to a pack-a-
day smoker.28,61 Females were used as women are more
susceptible to developing COPD.71,72
Drug treatments
Mice were treated daily by intraperitoneal (i.p.) injection
with the PP2A and TTP activator, AAL(S) (0.8 mg kg
1 in
200 lL of PBS, synthesised in-house); the proteasome
inhibitor, bortezomib (BORT: 0.2 mg kg1 in 200 lL of PBS,
LC laboratories, Woburn, USA); or combined treatments
(AAL(S) + BORT), daily before CS smoke exposure for four
days (acute) or for five days per week for eight weeks
(chronic). Doses used were based on previously published
work.64,65,73 Controls were vehicle-treated and exposed to
normal air for the same time periods.
Airway and parenchymal inflammation
Bronchoalveolar lavage (BAL) was performed, cells were
cytocentrifuged (300 g, 10 min) and stained with May–
Grunwald–Giemsa, and differential leucocyte counts were
determined according to morphological criteria from a total
of 250 cells as previously described.74–78 Lungs were
perfused, formalin-fixed, embedded and sectioned.
Longitudinal sections were stained with haematoxylin and
eosin (H&E), and parenchymal inflammation was assessed
by enumerating the numbers of inflammatory cells in 20
randomised high-power fields as described previously.20,21
mRNA expression
Whole lungs were collected and stored in RNA Stabilization
Reagent, RNAlater (Qiagen, Chadstone Centre, Vic,
Australia). RNA was extracted with guanidinium thiocyanate
phenol chloroform (TRIzol). Extracted RNA was treated with
DNAse I (Sigma, Castle Hill, NSW, Australia) and reverse-
transcribed using Bioscript (Bioline, Alexandria, NSW,
Australia) and random hexamer primers (Invitrogen, Mount
Waverley, Vic, Australia).21,59,79 The relative abundance of
cytokine transcripts for IL-6, TNF-a, CXCL1, CXCL2, fibronectin
(Fn) and matrix metalloproteinase-12 (MMP-12) was
determined relative to the reference gene hypoxanthine
phosphoribosyltransferase (HPRT) by real-time qPCR using a
ViiA 7 Real-Time PCR System (Life Technologies, Thermo
Fisher Scientific, Carlsbad, CA, USA). Custom-designed
primers (Integrated DNA Technologies, Coralville, Iowa, USA)
were used (Supplementary table 1).
Airway remodelling
Longitudinal lung sections were stained with H&E or
Masson’s trichrome. The area of collagen deposition (lm2),
airway epithelial area (lm2) and cell (nuclei) number were
assessed in a minimum of four small airways (basement
membrane [BM] perimeter < 1000 lm) per section. Data
were normalised to BM perimeter (lm) and quantified
using ImageJ software (Version 1.49h; National Institutes of
Health, New York City, NY, USA) 19,21,24,80.
Emphysema-like alveolar enlargement
H&E-stained longitudinal lung sections were assessed for
alveolar enlargement. Alveolar diameter was determined
using the mean linear intercept method, and the
percentage of alveolar destruction was determined using
destructive index method.19–22,30
Lung function
Lung function parameters were assessed using forced
oscillation (Flexivent, Scireq, Montreal, QC, Canada) and
forced manoeuvre (Buxco electronics, New Brighton, MN,
USA) techniques as previously described.20,24,50
Statistical analysis
Data are presented as means  sem with 5–8 mice in each
group and are representative of two independent
experiments. Statistical significance for multiple comparisons
was determined by one-way ANOVA with Bonferroni post-
test, or non-parametric equivalent, where appropriate using
GraphPad Prism V.6 Software (San Diego, CA, USA).
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